Munich - Delayed Quote EUR

Median Technologies (4ZG.MU)

2.6250

0.0000

(0.00%)

At close: April 15 at 8:04:24 AM GMT+2

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025

SOPHIA ANTIPOLIS, France, April 07, 2025--Regulatory News: Median Technologies (Paris:ALMDT):

Business Wire 8 days ago

ALMDT.PA
eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study

SOPHIA ANTIPOLIS, France, March 31, 2025--Regulatory News: Median Technologies (Paris:ALMDT) (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company"), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, disclosed today pivotal study RELIVE’s final results, which confirm and compl

Business Wire 15 days ago

ALMDT.PA
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025

SOPHIA ANTIPOLIS, France, March 07, 2025--Regulatory News: Median Technologies (Paris:ALMDT):

Business Wire last month

ALMDT.PA
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025

SOPHIA ANTIPOLIS, France, March 03, 2025--Median Technologies announces the availability of the preparatory documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025

Business Wire last month

ALMDT.PA
Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference

SOPHIA ANTIPOLIS, France, February 26, 2025--Median Technologies to present at TD Cowen’s 45th Annual Health Care Conference

Business Wire last month

ALMDT.PA
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology

SOPHIA ANTIPOLIS, France, February 24, 2025--Median to showcase its artificial intelligence Software as a Medical Device for lung cancer screening at the European Congress of Radiology.

Business Wire last month

ALMDT.PA
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025

SOPHIA ANTIPOLIS, France, February 11, 2025--Median Technologies_Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025

Business Wire 2 months ago

ALMDT.PA
Median Technologies Gives Update on Drawdowns of the Iris Equity Line

SOPHIA ANTIPOLIS, France, February 05, 2025--Median Technologies gives update on drawdowns of the Iris equity line

Business Wire 2 months ago

ALMDT.PA
Median Technologies completes clinical validation of cancer diagnostic software

Median Technologies now plans to submit its lung cancer diagnostic for regulatory clearance in the US and EU in the coming months.

Medical Device Network 2 months ago

ALMDT.PA
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions

SOPHIA ANTIPOLIS, France, February 03, 2025--Median Technologies: eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial

Business Wire 2 months ago

ALMDT.PA
Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook

SOPHIA-ANTIPOLIS, France, January 31, 2025--Median Technologies reports 2024 key financial indicators and 2025 outlook

Business Wire 2 months ago

ALMDT.PA
Median Technologies secures €47.5m to commercialise cancer diagnostic

Up to €37.5m of Median’s funding comes from the EIB, and €10m from an equity line with IRIS Capital Investment.

Medical Device Network 2 months ago

ALMDT.PA
Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU

SOPHIA ANTIPOLIS, France, January 24, 2025--Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization

Business Wire 2 months ago

ALMDT.PA
Median Technologies: Financial Communications Schedule for the First Half of 2025

SOPHIA ANTIPOLIS, France, January 14, 2025--Median Technologies Financial Communications Schedule for the First Half of 2025.

Business Wire 2 months ago

ALMDT.PA
Half Year Median Technologies Liquidity Contract Statement

SOPHIA ANTIPOLIS, France, January 09, 2025--Half year Median Technologies liquidity contract statement

Business Wire 3 months ago

ALMDT.PA
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024

SOPHIA ANTIPOLIS, France, January 08, 2025--Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2024.

Business Wire 3 months ago

ALMDT.PA
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30th, 2024

SOPHIA ANTIPOLIS, France, December 11, 2024--Regulatory News: Median Technologies (Paris:ALMDT):

Business Wire 4 months ago

ALMDT.PA
Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

SOPHIA ANTIPOLIS, France, November 26, 2024--Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

Business Wire 4 months ago

ALMDT.PA
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024

SOPHIA ANTIPOLIS, France, November 12, 2024--Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2024.

Business Wire 4 months ago

ALMDT.PA
Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis™ Lung Cancer Screening (LCS) REALITY Data

SOPHIA-ANTIPOLIS, France, November 07, 2024--Median Technologies hosted insightful Key Opinion Leader (KOL) webinar on eyonis™ Lung Cancer Screening (LCS) REALITY data.

Business Wire 5 months ago

ALMDT.PA

Performance Overview

Return	4ZG.MU	CAC 40 (^FCHI)
YTD	-29.81%	-0.61%
1-Year	-31.19%	-8.82%
3-Year	-80.05%	+11.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Median Technologies (4ZG.MU)

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025

eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025

Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025

Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference

Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025

Median Technologies Gives Update on Drawdowns of the Iris Equity Line

Median Technologies completes clinical validation of cancer diagnostic software

Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions

Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook

Median Technologies secures €47.5m to commercialise cancer diagnostic

Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU

Median Technologies: Financial Communications Schedule for the First Half of 2025

Half Year Median Technologies Liquidity Contract Statement

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30th, 2024

Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024

Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis™ Lung Cancer Screening (LCS) REALITY Data

Performance Overview